Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

From COVID to Nicotine Treatments, this Bio Stock is One to Watch

(Image via Lexaria Bioscience Corp.) There’s no shortage of excitement over potential COVID-19 vaccines. Just looking at the response to news around these developments is evidence of that, and one Company is working on a transformative, patented tech...
Stockhouse Editorial | December 1, 2020 |

Biopharma's Technology Could Render Drug Suitable for COVID-19 Treatment

How this could be achieved using the proprietary platform of TFF Pharmaceuticals and why it could work are discussed in a ROTH Capital Partners report. In an April 7 research note, ROTH Capital Partners analyst Jonathan Aschoff discussed the potential of app...
Streetwise Reports | April 9, 2020 |

Gold closely tracks debt-to-GDP ratio

The debt-to-GDP ratio is an important metric economists use for comparing a country’s total debt to its gross domestic product (GDP). The percentage arrived at by dividing the country’s total GDP by its total debt indicates the country&Close...
Richard (Rick) Mills | April 8, 2020 |

The coming supply crunch

As I write and you read, the world economy is getting pummeled, one blow after another, by demand destruction, as economies grind to a screeching halt due to unprecedented restrictions on economic and social activity owing to the relentless spread of the covid-19 coronavirus...
Richard (Rick) Mills | April 7, 2020 |

Texas Oilfield Services Firm 'Well Positioned for 2020'

The factors contributing to the company's status and financial expectations for this year are discussed in a Raymond James report. In a Jan. 21 research note, Raymond James analyst Praveen Narra reported that Halliburton Co. (HAL:NYSE) is "well positioned ...
Streetwise Reports | January 30, 2020 |

The Golden Bullet for Drug Delivery

It’s the Holy Grail in the cannabis industry. Everyone is trying to innovate the best delivery system to optimize the “bioavailability” (uptake) of medical cannabis in order to offer the perfect pairing -- precise dosing with a fast on...
Marc Davis | January 8, 2020 |

Does this Device Solve the Issue of Electromagnetic Radiation?

There is a large health issue that few know about and does not see much press, but it is there for everyone to see buried in the fine print when you buy most cell phones. I am talking about electromagnetic radiation (EMR) that is emitted with electronic devices, such as...
Streetwise Reports | January 7, 2020 |

Protagonist Therapeutics Shares Trade Up 70% on Phase 2 Transfusion Trial Results

Newark, Calif.-based Protagonist Therapeutics' shares traded 70% higher today after the firm reported preliminary Phase 2 results for Hepcidin Mimetic PTG-300 in the treatment of transfusion dependent beta-thalassemia. Clinical-stage biopharmaceutical company Protago...
Streetwise Reports | December 5, 2019 |

Kardashian-Style News Bomb: Already Big Ashram Gets Bigger And Bigger

Bigger is Better (at least in this respect) What a pleasant surprise! The Ashram Rare Earth and Fluorspar Deposit continues to grow. As announced today by Commerce Resources Corp. , recent core assays for vertical drilling at Ashram has disc...
Stephan Bogner | November 28, 2019 |

Phase 2 Data from Potential Multibagger Biopharma 'Checks All the Boxes'

The latest clinical trial results are dissected in a ROTH Capital Partners report. In a Sept. 26 research note, ROTH Capital Partners analyst Jerry Isaacson reported that AzurRx BioPharma Inc.'s (AZRX:NASDAQ) Phase 2 OPTION trial for lead candidate MS1819 in cystic ...
Streetwise Reports | October 1, 2019 |
1 2